ProKidney (NASDAQ:PROK - Get Free Report) is projected to release its earnings data before the market opens on Thursday, March 20th. Analysts expect ProKidney to post earnings of ($0.15) per share for the quarter.
ProKidney Price Performance
PROK traded up $0.03 during trading on Friday, hitting $0.98. 480,727 shares of the stock traded hands, compared to its average volume of 492,321. The firm has a market capitalization of $286.88 million, a P/E ratio of -1.79 and a beta of 1.38. The firm has a 50-day moving average of $1.48 and a 200 day moving average of $1.77. ProKidney has a 12-month low of $0.94 and a 12-month high of $4.44.
About ProKidney
(
Get Free Report)
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
Read More
Before you consider ProKidney, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProKidney wasn't on the list.
While ProKidney currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
